6 not yet recruiting, 1 recruiting. 3 Phase 1, 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Not yet recruiting 2, Recruiting 1 |
| Phase 3 | 3 | Not yet recruiting 3 |
| Phase 2 | 2 | Not yet recruiting 2 |
Follow Jiangxi Kvvit Pharmaceutical Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation DN022150+AG( Stage I ）, DN022150+AG（Stage II）, placebo+AG（Stage II） - Pancreatic Cancer, Pancreatic Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 465 | 2027-06-06 | 2026-06-18 |
| Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation DN022150, Chemotherapy - Pancreatic Cancer | Phase 3 | Not yet recruiting | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 360 | 2026-09-01 | 2026-07-08 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KR25102 in Healthy Volunteers KR25102 for Injection, Placebo for KR25102 for Injection - Healthy Volunteers (HV) | Phase 1 | Not yet recruiting | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 83 | 2026-06-01 | 2026-06-01 |
| A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of KR23248 Capsules in Healthy Adult Subjects KR23248, Matching Placebo - Schizophrenia | Phase 1 | Not yet recruiting | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 66 | 2026-05-19 | 2026-05-15 |
| Study of Single and Multiple Ascending Doses of KR23343 in Healthy Adult Participants KR23343, Matching Placebo - Healthy | Phase 1 | Recruiting | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 92 | 2026-02-05 | 2026-08-05 |
| Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris KR230109 cream 0.025%, KR230109 cream 0.05%, Placebo - Acne Vulgaris | Phase 2 | Not yet recruiting | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 180 | 2026-01-10 | 2026-01-15 |
| A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension Suraxavir Marboxil, Oseltamivir - Influenza | Phase 3 | Not yet recruiting | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 144 | 2025-08-01 | 2025-08-08 |
Pancreatic Neoplasms (2) · Acne Vulgaris (1) · Influenza, Human (1) · Schizophrenia (1)
Control Groups (1) · Drug Therapy (1) · Injections (1) · Oseltamivir (1)
China (2)
Guoping Yang (1)